Trial
NCT00092287
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ipsen
Collaborators
—
Condition
Malignant Carcinoid Syndrome
Intervention
lanreotide Autogel (somatostatin analogue)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-30